• Explore /
  • Poster
  • / Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).

Abstract Video & Slides Poster

Authors

Karim Fizazi

Karim Fizazi

Institut Gustave Roussy and University of Paris Sud, Villejuif, France

Karim Fizazi , Neal D. Shore , Teuvo Tammela , Albertas Ulys , Egils Vjaters , Sergey Polyakov , Mindaugas Jievaltas , Murilo Luz , Boris Alekseev , Iris Kuss , Marie-Aude Le Berre , Oana Petrenciuc , Amir Snapir , Toni Sarapohja , Matthew Raymond Smith

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02200614

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5514)

DOI

10.1200/JCO.2020.38.15_suppl.5514

Abstract #

5514

Poster Bd #

95

Abstract Disclosures

Similar Posters

Poster

2020 ASCO Virtual Scientific Program

DAROL: DARolutamide ObservationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients.

DAROL: DARolutamide ObservationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients.

First Author: Evan Y. Yu

First Author: Simon J. Crabb

First Author: Neal D. Shore

First Author: Karim Fizazi